PATENT CLAIM ANALYSIS

Application Number: 16093915
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "230500"]

Abstract:
The present invention provides N-[3-[2-Amino-5-(1,1-difluoroethyl)-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-(trifluoromethyl)pyridine-2-carboxamide, i.e. the compound of Formula I: [Formula should be inserted here] or a pharmaceutically acceptable salt thereof and in particular its (4aR,5S,7aS) isomer as a selective BACE1 inhibitor for treating e.g. Alzheimer's disease and the progression of mild cognitive impairment to Alzheimer's disease.

Claim (Index 2):
The compound or salt according to  claim 1  wherein the hydrogen at position 4a is in the cis configuration relative to the substituted phenyl at position 7a:

Metadata:
- Claim Count in Document: 3.0
- Percentile: 97.0
- Lexical Diversity: 1.36667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15045305', '15549674', '15135580', '14677113', '11574989']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7708527803969153
- 35 USC 102 Novelty (BERT): 0.5603960814997805
- Combined Prediction Score: 0.7498071105072017
- Mean Citation Score: 329.198442
- Max Citation Score: 432.92966
- Similarity Product: 310.50573695637706

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test